Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Amid market turbulence, high-yielding healthcare stocks are experiencing varied analyst sentiment. Johnson & Johnson (JNJ, 3.16% yield) and Medtronic (MDT, 3.15% yield) received increased price targets from analysts, supported by recent positive developments like JNJ's FDA submission for TREMFYA and MDT's CE Mark for its MiniMed system. In contrast, Baxter International (BAX, 3.13% yield) saw analysts cut price targets following its worse-than-expected second-quarter financial results and a lowered FY25 outlook, indicating diverging performance within the sector despite similar yield profiles.

Analysis

Within the healthcare sector, a notable divergence in analyst sentiment and fundamental outlook is apparent among high-yield dividend stocks, despite their comparable yields of approximately 3.15%. Medtronic (MDT) exhibits the most positive momentum, with analysts from Mizuho and Citigroup maintaining "Outperform" and "Buy" ratings while raising price targets to $100 and $99, respectively. This optimism is underpinned by a significant product catalyst: the recent CE Mark approval for its MiniMed 780G System. Similarly, Johnson & Johnson (JNJ) has seen analysts at Barclays and Guggenheim increase price targets to $176 and $167, supported by a recent FDA submission for its TREMFYA drug, although the underlying ratings remain neutral. In stark contrast, Baxter International (BAX) faces considerable headwinds, evidenced by its worse-than-expected Q2 financial results and a lowered full-year 2025 outlook. This poor performance prompted analysts at Citigroup and Wells Fargo to cut price targets to $32 and $33, highlighting significant operational challenges and justifying its strong negative sentiment score.

Key Decisions for Investors

• Investors should look beyond similar dividend yields and focus on company-specific fundamentals, as the diverging analyst ratings between Medtronic, Johnson & Johnson, and Baxter demonstrate varied performance outlooks within the same sector.
• Medtronic may be attractive for those seeking growth in the high-yield healthcare space, given its strong positive sentiment, 'Buy' ratings, and a clear product catalyst with the MiniMed 780G System approval.
• A cautious stance on Baxter International is warranted due to its recent earnings miss, lowered corporate guidance, and corresponding price target reductions, which signal significant near-term risks.
• For Johnson & Johnson, investors should monitor the progress of its TREMFYA sBLA submission with the FDA, as a positive outcome could serve as a key catalyst supporting the recent price target increases.